Intech Investment Management LLC Increases Holdings in Illumina, Inc. $ILMN

Intech Investment Management LLC grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 1,175.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,303 shares of the life sciences company’s stock after buying an additional 33,457 shares during the quarter. Intech Investment Management LLC’s holdings in Illumina were worth $4,762,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Baker Avenue Asset Management LP raised its position in shares of Illumina by 14.9% during the 4th quarter. Baker Avenue Asset Management LP now owns 4,399 shares of the life sciences company’s stock valued at $577,000 after buying an additional 570 shares in the last quarter. Huntington National Bank raised its position in shares of Illumina by 95.5% during the 4th quarter. Huntington National Bank now owns 1,208 shares of the life sciences company’s stock valued at $158,000 after buying an additional 590 shares in the last quarter. Geode Capital Management LLC raised its position in Illumina by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after purchasing an additional 130,139 shares during the period. Allstate Corp raised its position in Illumina by 96.7% in the 4th quarter. Allstate Corp now owns 11,170 shares of the life sciences company’s stock worth $1,465,000 after purchasing an additional 5,492 shares during the period. Finally, Choate Investment Advisors purchased a new stake in Illumina in the 4th quarter worth about $2,553,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Performance

Illumina stock opened at $162.96 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a market capitalization of $24.66 billion, a P/E ratio of 29.63, a price-to-earnings-growth ratio of 2.70 and a beta of 1.50. The company’s 50-day moving average is $133.73 and its 200 day moving average is $132.09. Illumina, Inc. has a 1-year low of $78.79 and a 1-year high of $165.37.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts forecast that Illumina, Inc. will post 5.2 EPS for the current year.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent analyst reports. Weiss Ratings lowered shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Robert W. Baird set a $137.00 price objective on shares of Illumina in a research report on Friday, February 6th. Citigroup increased their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research report on Thursday, May 14th. Finally, Canaccord Genuity Group reduced their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $137.75.

Insider Transactions at Illumina

In other Illumina news, Director Keith A. Meister sold 225,067 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total value of $32,758,501.85. Following the transaction, the director directly owned 3,604,441 shares in the company, valued at $524,626,387.55. This represents a 5.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the transaction, the senior vice president owned 15,056 shares in the company, valued at $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 330,160 shares of company stock worth $48,028,308 over the last 90 days. Insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.